Seven members of the PTC Therapeutics team joined 11 HD-CAB team members for an advisory board on the 3rd November. Sian O’Neill, Senior Director of Patient Engagement EMEA & AP wrote following the meeting to say “Thank you again for the opportunity to participate in the 1st HD-CAB. It was a pleasure to meet such an amazing group of people. The CAB team has pushed the PTC team into overdrive! The real and honest sharing of the reality of HD has generated a lot of questions and dare I say shifted the thought process for our team.”
Nouvelles
Roche/Genentech fait le point sur l'étude GENERATION HD2
Roche/Genentech annoncent que l'étude de phase II GENERATION HD2 est maintenant ouverte. C'est une excellente nouvelle pour la communauté internationale puisqu'il est prévu de la mener dans 15 pays (Argentine, Autriche, Australie, Canada, Danemark, France, Lire la suite...